SWOG clinical trial number
SWOG-9205

Central Prostate Cancer Serum Repository Protocol

Closed
Phase
Abbreviated Title
Ancillary Prostate
Activated
10/01/1992
Closed
10/01/2006
Participants
NCORP, Members, UCOP, Medical Oncologists, Surgeons, Pathologists, Affiliates

Research committees

Genitourinary Cancer

Eligibility Criteria Expand/Collapse

Pt must be eligible for and registered to a SWOG protocol for carcinoma of the prostate. Pts must submit greater than/equal to 3 ml of unthawed serum from baseline.

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase